Nurix Therapeutics (NRIX) Share-based Compensation (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Share-based Compensation for 8 consecutive years, with $18.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Share-based Compensation rose 74.02% year-over-year to $18.1 million; the TTM figure through May 2026 stood at $1.7 million (down 95.31% YoY), while the FY2025 annual figure was $20000.0, down 99.94% from the prior year.
• Share-based Compensation advanced to $18.1 million in Q2 2026 per NRIX's latest filing, from $2.7 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $85.9 million in Q3 2022 and bottomed at -$28.9 million in Q4 2025.
• Historically, Share-based Compensation has averaged $15.4 million across 5 years, with a median of $8.8 million in 2024.
• On a YoY basis, Share-based Compensation climbed as much as 38356.52% in 2024 and fell as far as 61580.0% in 2024.
• Nurix Therapeutics' Share-based Compensation stood at $28.1 million in 2022, then rose by 19.44% to $33.6 million in 2023, then retreated by 2.88% to $32.6 million in 2024, then slumped by 188.44% to -$28.9 million in 2025, then soared by 162.62% to $18.1 million in 2026.
• Business Quant data shows NRIX's Share-based Compensation at $18.1 million in Q2 2026, $2.7 million in Q1 2026, and -$28.9 million in Q4 2025.